Lamivudine in the treatment of HBV-related liver disease after renal transplantation: An update

Fabrizio Fabrizi, Paul Martin, S. Bunnapradist, M. Villa, E. Rusconi, P. G. Messa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Diminished survival due to hepatitis B has been observed after renal transplantation (RT). Lamivudine, a second-generation nucleoside analogue, has been approved for the treatment of chronic hepatitis B virus (HBV) infection in patients with normal renal function. Numerous clinical experiences with lamivudine after RT have been recently published. Despite numerous shortcomings, all of these reports have shown encouraging results. The rate of clearance of HBV viremia ranged between 67% and 100%, and the frequency of ALT normalization was between 50% and 100% with lamivudine use. Even patients with fibrosing cholestatic hepatitis, a serious form of HBV-related liver disease with ominous course, have been successfully treated with lamivudine. Lamivudine therapy significantly improved the survival of HBsAg positive renal allograft recipients. However, numerous issues concerning the treatment of hepatitis B after RT remain unclear: the optimal time to initiate lamivudine, the appropriate duration of antiviral therapy after RT, and the role for pre-transplantation liver biopsy. Also, the management of lamivudine resistance remains a concern for physicians. Clinical trials are under way.

Original languageEnglish
Pages (from-to)211-221
Number of pages11
JournalInternational Journal of Artificial Organs
Volume28
Issue number3
StatePublished - Mar 1 2005
Externally publishedYes

Fingerprint

Lamivudine
Viruses
Hepatitis B virus
Liver
Kidney Transplantation
Liver Diseases
Biopsy
Hepatitis B
Therapeutics
Kidney
Viremia
Chronic Hepatitis B
Virus Diseases
Hepatitis B Surface Antigens
Nucleosides
Liver Transplantation
Hepatitis
Antiviral Agents
Allografts
Clinical Trials

Keywords

  • Hepatitis B virus
  • Lamivudine
  • Liver disease
  • Renal transplantation

ASJC Scopus subject areas

  • Biophysics

Cite this

Lamivudine in the treatment of HBV-related liver disease after renal transplantation : An update. / Fabrizi, Fabrizio; Martin, Paul; Bunnapradist, S.; Villa, M.; Rusconi, E.; Messa, P. G.

In: International Journal of Artificial Organs, Vol. 28, No. 3, 01.03.2005, p. 211-221.

Research output: Contribution to journalArticle

Fabrizi, F, Martin, P, Bunnapradist, S, Villa, M, Rusconi, E & Messa, PG 2005, 'Lamivudine in the treatment of HBV-related liver disease after renal transplantation: An update', International Journal of Artificial Organs, vol. 28, no. 3, pp. 211-221.
Fabrizi, Fabrizio ; Martin, Paul ; Bunnapradist, S. ; Villa, M. ; Rusconi, E. ; Messa, P. G. / Lamivudine in the treatment of HBV-related liver disease after renal transplantation : An update. In: International Journal of Artificial Organs. 2005 ; Vol. 28, No. 3. pp. 211-221.
@article{42cddfdce0e54e61934b2c8e335f5736,
title = "Lamivudine in the treatment of HBV-related liver disease after renal transplantation: An update",
abstract = "Diminished survival due to hepatitis B has been observed after renal transplantation (RT). Lamivudine, a second-generation nucleoside analogue, has been approved for the treatment of chronic hepatitis B virus (HBV) infection in patients with normal renal function. Numerous clinical experiences with lamivudine after RT have been recently published. Despite numerous shortcomings, all of these reports have shown encouraging results. The rate of clearance of HBV viremia ranged between 67{\%} and 100{\%}, and the frequency of ALT normalization was between 50{\%} and 100{\%} with lamivudine use. Even patients with fibrosing cholestatic hepatitis, a serious form of HBV-related liver disease with ominous course, have been successfully treated with lamivudine. Lamivudine therapy significantly improved the survival of HBsAg positive renal allograft recipients. However, numerous issues concerning the treatment of hepatitis B after RT remain unclear: the optimal time to initiate lamivudine, the appropriate duration of antiviral therapy after RT, and the role for pre-transplantation liver biopsy. Also, the management of lamivudine resistance remains a concern for physicians. Clinical trials are under way.",
keywords = "Hepatitis B virus, Lamivudine, Liver disease, Renal transplantation",
author = "Fabrizio Fabrizi and Paul Martin and S. Bunnapradist and M. Villa and E. Rusconi and Messa, {P. G.}",
year = "2005",
month = "3",
day = "1",
language = "English",
volume = "28",
pages = "211--221",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Lamivudine in the treatment of HBV-related liver disease after renal transplantation

T2 - An update

AU - Fabrizi, Fabrizio

AU - Martin, Paul

AU - Bunnapradist, S.

AU - Villa, M.

AU - Rusconi, E.

AU - Messa, P. G.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Diminished survival due to hepatitis B has been observed after renal transplantation (RT). Lamivudine, a second-generation nucleoside analogue, has been approved for the treatment of chronic hepatitis B virus (HBV) infection in patients with normal renal function. Numerous clinical experiences with lamivudine after RT have been recently published. Despite numerous shortcomings, all of these reports have shown encouraging results. The rate of clearance of HBV viremia ranged between 67% and 100%, and the frequency of ALT normalization was between 50% and 100% with lamivudine use. Even patients with fibrosing cholestatic hepatitis, a serious form of HBV-related liver disease with ominous course, have been successfully treated with lamivudine. Lamivudine therapy significantly improved the survival of HBsAg positive renal allograft recipients. However, numerous issues concerning the treatment of hepatitis B after RT remain unclear: the optimal time to initiate lamivudine, the appropriate duration of antiviral therapy after RT, and the role for pre-transplantation liver biopsy. Also, the management of lamivudine resistance remains a concern for physicians. Clinical trials are under way.

AB - Diminished survival due to hepatitis B has been observed after renal transplantation (RT). Lamivudine, a second-generation nucleoside analogue, has been approved for the treatment of chronic hepatitis B virus (HBV) infection in patients with normal renal function. Numerous clinical experiences with lamivudine after RT have been recently published. Despite numerous shortcomings, all of these reports have shown encouraging results. The rate of clearance of HBV viremia ranged between 67% and 100%, and the frequency of ALT normalization was between 50% and 100% with lamivudine use. Even patients with fibrosing cholestatic hepatitis, a serious form of HBV-related liver disease with ominous course, have been successfully treated with lamivudine. Lamivudine therapy significantly improved the survival of HBsAg positive renal allograft recipients. However, numerous issues concerning the treatment of hepatitis B after RT remain unclear: the optimal time to initiate lamivudine, the appropriate duration of antiviral therapy after RT, and the role for pre-transplantation liver biopsy. Also, the management of lamivudine resistance remains a concern for physicians. Clinical trials are under way.

KW - Hepatitis B virus

KW - Lamivudine

KW - Liver disease

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=18744387770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744387770&partnerID=8YFLogxK

M3 - Article

C2 - 15818543

AN - SCOPUS:18744387770

VL - 28

SP - 211

EP - 221

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 3

ER -